NextCure (NXTC) Insider Borgman Anne Elizabeth Buys 2,340 Shares

On June 18, 2026, Borgman Anne Elizabeth purchased 2,340 shares of NXTC. This insider transaction was not part of a planned trading program.

Insider Buying and Selling at NextCure, Inc.

Several insiders at NXTC made purchases on June 18, 2026. Borgman Anne Elizabeth, Ellen Feigal, Elaine Jones, John Houston, Stephen Webster, and David Kabakoff all bought shares. Each, except Kabakoff, acquired 2,340 shares, while Kabakoff purchased 3,510 shares. These transactions were not conducted under Rule 10b5-1 plans, indicating they were discretionary buys.

Other Institutional Activity in NXTC

In other institutional activity, Squadron Capital Management LLC increased its stake in NXTC by 28,034 shares, bringing its total to 265,000 shares valued at approximately $2.83 million, an 11.8% increase. Affinity Asset Advisors, LLC reduced its holdings by 5,468 shares, now holding 241,826 shares worth about $2.58 million, a 2.2% decrease. Ikarian Capital, LLC and Sofinnova Investments, Inc. held their positions steady, with 238,303 and 222,654 shares respectively. Vanguard Capital Management LLC opened a new position with 160,473 shares valued at about $1.69 million.

Analysts Set New Price Targets

Analysts have been active with their assessments of NXTC. On May 11, 2026, Lucid Capital Markets initiated coverage with a 'buy' rating and a price target of $25. Ladenburg Thalmann had previously upgraded the stock to 'buy' with an $18 target. Piper Sandler and HC Wainwright & Co. also maintained their 'buy' ratings in recent months, setting targets at $15 and $3 respectively.

Bottom Line

Borgman Anne Elizabeth's purchase of NXTC shares on June 18, 2026, adds to the insider activity at the company. NXTC's stock traded at $1.75 on Tuesday, reflecting its current market position. Institutional and analyst activity shows ongoing interest, with new positions and reiterated buy ratings, suggesting a focus on the company's future potential.